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GASTRIC CANCER TREATMENT – LONG TERM RESULTS 
 
A. DIBRA*, X. DRAÇINI, E. CELIKU, E. SADIKU, A. HOXHA, G. MERO, D. GODAJ, D. SHEHI 
 
Medical University of Tirana, “Mother Teresa” University Hospital Center, Tirana, Albania 
 
Objective: Gastric cancer is one of the most frequent malignancies heaving surgical treatment in our country.  The aim of this 
work is to offer an overview of the long-term performance of the patients after treated surgically for the diagnosis of gastric 
cancer. And also to evidence that in Albania it is absolutely necessary the standardization of an interdisciplinary therapeutic 
protocol for the treatment of gastric cancer. 
Methods: We consider the medical data of 624 patients treated in the First Sugical Clinic, UHC “Mother Theresa”, from 
January 2000 to December 2010 in elective surgery for gastric cancer. All patients or their relatives went contacted by phone 
in March 2012.  Only 107 of the patients could be reached (17 %), in the other cases, the contact number was not available. 
We presented a questionnaire, focused on informative elements on their post-operative treatments and its course. 
Results: According to the lates UICC/AJCC - TNM classification, the staging at the time of the diagnosis was: stage 1 - 49 
(8%) patients; stage 2 - 174 (28%) patients; stage 3 - 213 (34%) patients and stage 4 - 188 (30%) patients. The overall 
operability index was 70%;  188 (30%) patients resulted inoperable. Among the contacted patients, in 71% of them a curative-
intent intervention was performed. 27 patients were found alive (25,2%). 11 patients (10,3%) had a more than 5 years survival 
and apparently disease free after surgery. 5 patients had different causes of death, rather than the gastric disease.  
Conclusions: From the total of 107 patients that could be reached, 36,4% had underwent chemotherapy after the surgery, and 
5,6% had underwent radiotherapy. In 22,4% of them, the diagnosis of the recurrence was made. The mean time of recurrence 
diagnosis was 9 months after surgery (range from 1 month to 3 years). Between patients founded alive, 14 perform regular 
check-ups, as advised by their physician; 8 had performed only one check-up after finishing the treatment, and 5 never 
performed a check-up after surgery. 
 
 
CLINICAL AND IMMUNOLOGICAL IMPACT OF EARLY POSTOPERATIVE ENTERAL 
IMMUNONUTRITION AFTER TOTAL GASTRECTOMY IN GASTRIC CANCER PATIENTS: A 
PROSPECTIVE RANDOMIZED STUDY 
 
L. MARANO*, G. REDA, R. PORFIDIA, M. GRASSIA, M. PETRILLO, G. ESPOSITO, M. PEZZELLA,  
B. BRACCIO, P. GALLO, N. DI MARTINO 
 
VIII General and Gastrointestinal Surgery, Second University of Naples, Naples, Italia 
 
Objective: Enteral immunodiet has been gaining increasing attention, but experimental data of its clinical effects in patients 
with gastric cancer are inconsistent, contradictory  and poorly investigated. The aim of this study was to assess the impact of 
early postoperative enteral immunonutrition on clinical and immunological outcomes in an homogeneous group of gastric 
cancer patients submitted to total gastrectomy.  
Methods: One hundred and nine patients with gastric cancer were randomized to receive early postoperative enteral 
immunonutrition (formula supplemented with arginine, omega-3 fatty acids and ribonucleic acid (RNA)) or an isocaloric-
isonitrogenous control. The postoperative outcome was evaluated based on clinical variables, including postoperative 
infectious complications, anastomotic leak rate and length of hospitalization. In addition state of cellular immunity was 
evaluated and compared between the two groups. 
Results: The incidence of postoperative infectious complications in the immunodiet group (7.4%) was significantly (p<0.05) 
lower than that of the control group (20%), as well as the anastomotic leak rate (3.7% in immunodiet group vs 7.3% in 
standard nutrition group, p<0.05). Mortality rate did not show any significant differences; patients of the immunodiet group 
were found to have a significantly reduced length of hospitalization (12.7±2.3 days) when compared to standard diet group 
(15.9±3.4 days, p=0.029). The data on cellular immunity showed that the postoperative CD4+T-cell counts decreased in both 
groups, but the reduction in the IED group was significantly higher (p = 0.032) compared with the SND group.  
Conclusions: Early postoperative enteral immunonutrition significantly improves clinical and immunological outcomes in 
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IMPACT OF EARLY ENTERAL NUTRITION AND TOTAL PARENTERAL NUTRITION AFTER 
TOTAL GASTRECTOMY IN GASTRIC CANCER PATIENTS: THE “G. PAOLO II” CANCER 
CENTER EXPERIENCE 
 
R. DE LUCA*, S. MONTEMURRO, C. CALIANDRO, E. RUGGIERI, A. RUCCI, N. SILVESTRIS 
 
Department of Surgical Oncology, National Cancer Research Centre "G. Paolo II", Bari, Italia 
 
Objective: To assess the impact of early enteral nutrition (EEN) and total parenteral nutrition (TPN) on the postoperative 
course in terms of morbidity and mortality following total gastrectomy for gastric cancer. 
Methods: Two hundred and sixty-two consecutive pts (184 M; 78 F average age 64.2, range 30-91) underwent total 
gastrectomy for GC. Group A (108) was managed without EEN and TPN. Group B (154) received EEN and TPN. Enteral 
feeding, Protina G® by naso-jejunal tube associated with TPN started within 24 hours postoperatively. Enteral flow was 
controlled by means of a peristaltic pump. The initial rate of 10 ml/h was progressively increased to 20 ml/h per day until 
reaching the full nutritional goal (28 Kcal/kg per day). At 7th postoperative day routinely hydro soluble contrast through oral 
route was performed to rule out anastomotic leakage. In case of leakage Jejunal tube was not removed since contrast imaging 
assessed the integrity of anastomosis. Thereafter, oral fluid intake and subsequent regular diet started. 
Results: Overall morbidity and mortality were 29% vs 12% and 14% and 3.5%, respectively in groups A and B (p<0.005). 
Morbidity and mortality were different between R0 and R1-R2 resections (R0: 28% vs 11 and 8% vs 0.7% respectively in 
groups A and B( p<0.005); R1-R2 resections: 30% vs 12.3% and 23% vs 8% respectively in groups A and B (p<0.005). 
Conclusions: In our experience postoperative EEN and TPN were associated with significant reductions in total 





MAST CELL POSITIVE TO TRYPTASE CORRELATES WITH METASTATIC LYMPH NODES IN 
GASTROINTESTINAL CANCERS PATIENTS SURGICALLY TREATED 
 
M. AMMENDOLA*, R. SACCO, G. SAMMARCO, R. ROMANO, C. FOLLIERO, A. ZULLO, S. 
MONTEMURRO, G. RANIERI 
 
Chair of Clinical Surgery, University of "Magna Graecia" Medical School, Catanzaro, Italia 
Surgery Unit, National Cancer Institute Giovanni Paolo II, Bari, Italia 
Interventional Radiology Unit with Integrated Section of Translational Medical Oncology National Cancer Research Centre, 
National Cancer Institute Giovanni Paolo II, Bari, Italia 
 
Objective: Angiogenesis has been found to be a reliable prognostic indicator for several types of malignancies. Tryptase is a 
serin protease stored in mast cells’ granules, which plays a role in tumour angiogenesis. Mast cells (MCs) can release tryptase 
following c-Kit receptor activation.  
Methods: In this study, immunohistochemistry, image analysis methods and clinical aspects were used in a series of 41 
gastrointestinal cancer patients with stage T3-4N2a-bM0 (by AJCC for CRC 7th Edition) and T3N2-3M0 (by AJCC for Gastric 
Cancer 7th Edition) to evaluate the correlation between tryptase number in tumour and the number of metastatic lymph nodes 
harvested.  
Results: Data demonstrated a positive correlation between the number of tryptase in tumour tissue and the number of 
metastatic lymph nodes; the validity of this data needs confirmation by a larger number of cases. 
Conclusions: This is the first report considering tryptase in tumour tissue as a useful tool for a valid indication of the type of 
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A CASE OF FAMILIAL DIFFUSE GASTRIC CANCER WITH A NONSENSE MUTATION OF CDH1 
GENE 
 
M. BENCIVENGA*, S. GIACOPUZZI, G. DE MANZONI 
 
Chirurgia Esofago e Stomaco, Università di Verona, Verona, Italia 
 
Objective: Hereditary Diffuse Gastric Cancer is an autosomal dominant cancer syndrome related in about 40% of cases to 
germline mutations of CDH1 gene encoding E-cadherin protein. Constitutional CDH1 gene mutations are also detected in 
early onset sporadic diffuse Gastric Cancer. We aimed to evaluate frequency of CDH1 gene mutations in patients with early 
onset diffuse gastric cancer or with a familial diffuse Gastric Cancer that do not fulfil criteria for HDGC in a single 
Institution. 
Methods: A CDH1 gene screening was performed in 16 patients with a diffuse Gastric Cancer diagnosed before 35 years of 
age or with a familial diffuse Gastric Cancer .  
Results: A new germinal mutation of CDH1 gene was found in a 40 years-old Caucasian women with a family history of 
Gastric Cancer (one first-degree and two second-degree relatives affected with unknown histotype) It is a nonsense mutation 
located in exon 6 (E261X; GAA>TAA). It has been confirmed by a second genetic testing performed in another research 
center. 
Conclusions: Screening of CDH1 gene in a case of familial diffuse Gastric Cancer led to the discovery of a new CDH1 
germline mutation. As it is a nonsense mutation its pathogenetic role is clear. Actually we are performing CDH1 genetic 
testing on relatives because a profilactic total gastrectomy should be offered to nonsense CDH1 germline mutation carriers of 
20 year of age or older. 
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